{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.9","upperLimit":"69.2","value":"36.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Percent of patients and the 95% Binomial Confidence interval who had any stage I-IV acute GvHD based on the modified Keystone Grading Scale for skin, liver and gastrointestinal symptoms for patients in Phase II. Zero means no acute GvHD was reported, and higher stages are worse outcomes (range of 0-4).\n\nFor skin: 0=no rash; 1=erthematous macular rash over \\<25% body surface; 2=over 25-50% of body surface; 4=bullae, exfoliation ulcerative dermatitis.\n\nFor liver (bilirubin (mg/dL)): 0= \\<2.0; 1= 2-\\<2.9; 3= 3-\\<5.9; 4= \\>=15 . For gut changes (diarrhea\\[ml/day\\]): 0=none; 1= \\>500-1000; 2= \\>1000-1500; 3= \\>1500; 4=severe abdominal pain with or without ileus.\n\nOverall grade 0: Skin=0; liver=0; gut changes=0. Overall grade 1: Skin with 1 or 2; liver=0; gut changes=0. Overall grade 2: Skin with 1, 2, or 3; liver=1; gut changes=1. Overall grade 3: Skin with 2 or 3; liver with 2 or 3; gut changes with 2 or 3. Overall grade 4: Patients with grade 4 toxicity in any organ system.","dispersionType":"95% Confidence Interval","groups":[{"description":"Standard treatment of sirolimus and tacrolimus as GvHD prophylaxis with sirolimus (target plasma drug level of 5-10 ng/ml) and lenalidomide (15 mg daily) as post-transplant maintenance","id":"OG000","title":"Phase II"}],"paramType":"NUMBER","populationDescription":"All patients who received treatment and were followed after transplant","reportingStatus":"POSTED","timeFrame":"Day 0 through 1 year post transplantation","title":"Phase II - Percent of Patients With Acute Graft Versus Host Disease (GvHD)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}